Q-omics provides the consensus-scored NPIPB10P profile across patient tissues and cancer cell-line models. NPIPB10P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NPIPB10P is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, NPIPB10P RNA expression shows 11,331 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, COAD, and UVM as cancer lineages where NPIPB10P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPIPB10P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPIPB10P survival associations across molecular data types. NPIPB10P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPIPB10P RNA expression–survival associations across cancer types. High NPIPB10P expression shows unfavorable associations in STAD, KIRP and COAD, but favorable associations in BLCA, SKCM and PCPG. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for NPIPB10P RNA expression.
This table summarizes NPIPB10P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for NPIPB10P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPIPB10P shows higher tumor expression in COAD, KIRP, KIRC, UCEC, HNSC and ESCA. The COAD box plot shows higher NPIPB10P RNA expression in tumor versus normal tissue (log2 FC = +0.290, t-test p < 0.001).
This table shows molecular features associated with NPIPB10P in patient tissues and cancer cell lines. In patient samples, NPIPB10P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
